Skip to main content

DexCom, Inc.

corporate_fare Company Profile

DexCom, Inc.

DXCM·NASDAQ·Industrial Applications And Services·CIK 0001093557

Dexcom, Inc. is a medical device company that designs, develops, and sells continuous glucose monitoring (CGM) systems for managing diabetes and metabolic health. These systems are used by patients, caregivers, and clinicians globally. The company commercialized its first product in 2006 after receiving FDA approval. Dexcom launched its latest generation system, the Dexcom G7 Continuous Glucose Monitoring System (G7), in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System (G7 15 Day) in late 2025. In August 2024, Dexcom introduced Stelo, a biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin, marking the first over-the-counter glucose biosensor in the U.S. The G7 system received Conformité Européenne Marking (CE Mark) approval in March 2022 and marketing authorization from the FDA in December 2022 through the 510(k) review process. The G7 is classified as a Class II integrated continuous glucose monitoring system (iCGM) by the FDA, subject to special controls for accuracy, reliability, and clinical relevance. Its technical performance, including the glucose value algorithm, communication with display and mobile devices, and compatibility with Dexcom Clarity (cloud-based reporting software), is substantially equivalent to the prior generation Dexcom G6 Continuous Glucose Monitoring Integrated System (G6). The G7 is cleared in the United States for all people with diabetes aged two years and older.

DexCom, Inc. (NASDAQ:DXCM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for DXCM at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Dexcom Reports Strong Preliminary Q4 & FY2025 Results, Issues Positive 2026 Revenue and Margin Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.66B
Net Income
$836.3M
Diluted EPS
$2.09
Op. Cash Flow
$1.44B
Free Cash Flow
$1.08B
Gross Profit
$2.8B
Operating Income
$911.8M
Cash & Equivalents
$917.7M
Debt / Equity
0.00×
Net Margin
17.9%
Shares Outstanding
384.8M sh
Source: 10-K · filed 2026-02-12 · accession 0001093557-26-000027
$78.18 -1.44% today
52-week range · as of 2026-10-29 $54.11 – $92.59
Market cap
$29.58B
Volume
4.6M (1.0× avg)
3-mo avg 4.7M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DXCM - Filings & News (Page 2)

DXCM
Jan 12, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.89
Real-time Price: $78.18 info
Change: +$10.29 (+15%) info
Market Cap: $29.582B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets